Eliquis (Apixaban)’s generic companies stop selling one after another. This is a strategy after the Supreme Court ruled in favor of the original company BMS in the Eliquis patent dispute.

This is a measure to reduce the risk even a little in preparation for future lawsuits for claiming damages.

According to the pharmaceutical industry on the 13th, Chong Kun Dang, Yuhan Corporation, Samjin Pharm, and Hanmi Pharm, which are selling Eliquis generics, have either stopped or stopped selling the product.

An official from a company selling generics said, "We have already stopped selling them." An official from another pharmaceutical company also said, "We are actively considerin